Agnieszka Boesen

Array ( [id] => 13805121 [patent_doc_number] => 10179822 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-01-15 [patent_title] => Humanized monoclonal antibodies and methods of use [patent_app_type] => utility [patent_app_number] => 15/349516 [patent_app_country] => US [patent_app_date] => 2016-11-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 21 [patent_figures_cnt] => 20 [patent_no_of_words] => 11513 [patent_no_of_claims] => 24 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 100 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15349516 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14372503 [patent_doc_number] => 20190160164 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-05-30 [patent_title] => ROTAVIRUS VACCINES [patent_app_type] => utility [patent_app_number] => 15/774416 [patent_app_country] => US [patent_app_date] => 2016-11-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 44152 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -62 [patent_words_short_claim] => 23 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15774416 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14406783 [patent_doc_number] => 20190169235 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-06-06 [patent_title] => MODIFIED PROTEIN ENCODING SEQUENCES HAVING INCREASED RARE HEXAMER CONTENT [patent_app_type] => utility [patent_app_number] => 15/773685 [patent_app_country] => US [patent_app_date] => 2016-11-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16322 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15773685 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12963205 [patent_doc_number] => 09873922 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-01-23 [patent_title] => Method for reduction or elimination of false-negative enzyme immunoassay and polymerase chain reaction testing results [patent_app_type] => utility [patent_app_number] => 15/342471 [patent_app_country] => US [patent_app_date] => 2016-11-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 4907 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 151 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15342471 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13508245 [patent_doc_number] => 20180305665 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-10-25 [patent_title] => Method for Enrichment and Expansion of Virus Antigen-Specific T Cells [patent_app_type] => utility [patent_app_number] => 15/769872 [patent_app_country] => US [patent_app_date] => 2016-10-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 5419 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -10 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15769872 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11554231 [patent_doc_number] => 20170100477 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-04-13 [patent_title] => 'Methods of Immunizing a Subject and Compositions Related Thereto' [patent_app_type] => utility [patent_app_number] => 15/289705 [patent_app_country] => US [patent_app_date] => 2016-10-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 4 [patent_no_of_words] => 8998 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15289705 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16042971 [patent_doc_number] => 10683344 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-06-16 [patent_title] => Antibodies that potently neutralize hepatitis B virus and uses thereof [patent_app_type] => utility [patent_app_number] => 15/766703 [patent_app_country] => US [patent_app_date] => 2016-10-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 39 [patent_figures_cnt] => 26 [patent_no_of_words] => 40731 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 95 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15766703 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11866173 [patent_doc_number] => 20170233458 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-08-17 [patent_title] => 'METHOD OF MANUFACTURING INTRAVENOUS IMMUNOGLOBULIN FROM FRACTION III' [patent_app_type] => utility [patent_app_number] => 15/278729 [patent_app_country] => US [patent_app_date] => 2016-09-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 3 [patent_no_of_words] => 2268 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15278729 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14621889 [patent_doc_number] => 20190224312 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-07-25 [patent_title] => Methods of Using Low Dose Volume B-cell Epitope Compositions for Inducing an Antibody Immune Response in Human Subjects [patent_app_type] => utility [patent_app_number] => 16/336162 [patent_app_country] => US [patent_app_date] => 2016-09-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 28249 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 56 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16336162 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11527248 [patent_doc_number] => 20170087225 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-03-30 [patent_title] => 'COMPOSITIONS AND METHODS FOR LATENT VIRAL TRANSCRIPTION REGULATION' [patent_app_type] => utility [patent_app_number] => 15/277675 [patent_app_country] => US [patent_app_date] => 2016-09-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 6 [patent_no_of_words] => 10232 [patent_no_of_claims] => 23 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15277675 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13899045 [patent_doc_number] => 20190038727 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-02-07 [patent_title] => METHODS FOR COMBINING ADOPTIVE T CELL THERAPY WITH ONCOLYTIC VIRUS ADJUNCT THERAPY [patent_app_type] => utility [patent_app_number] => 15/757687 [patent_app_country] => US [patent_app_date] => 2016-09-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 18965 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -30 [patent_words_short_claim] => 67 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15757687 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11756081 [patent_doc_number] => 20170202948 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-07-20 [patent_title] => 'VACCINE COMPOSITIONS HAVING IMPROVED STABILITY AND IMMUNOGENICITY' [patent_app_type] => utility [patent_app_number] => 15/257436 [patent_app_country] => US [patent_app_date] => 2016-09-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 103 [patent_figures_cnt] => 103 [patent_no_of_words] => 25484 [patent_no_of_claims] => 28 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15257436 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11350585 [patent_doc_number] => 20160369325 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-12-22 [patent_title] => 'METHOD FOR EVALUATION OF VIABILITY OF VIRUSES WITH LYMPHOTROPISM PROPERTIES' [patent_app_type] => utility [patent_app_number] => 15/257663 [patent_app_country] => US [patent_app_date] => 2016-09-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 5028 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15257663 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11395179 [patent_doc_number] => 20170015713 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-01-19 [patent_title] => 'Fusion Protein Comprising Diphtheria Toxin Non-Toxic Mutant CRM197 or Fragment Thereof' [patent_app_type] => utility [patent_app_number] => 15/248850 [patent_app_country] => US [patent_app_date] => 2016-08-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 28 [patent_figures_cnt] => 28 [patent_no_of_words] => 16592 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15248850 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11393971 [patent_doc_number] => 20170014506 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-01-19 [patent_title] => 'Fusion Protein Comprising Diphtheria Toxin Non-Toxic Mutant CRM197 or Fragment Thereof' [patent_app_type] => utility [patent_app_number] => 15/248779 [patent_app_country] => US [patent_app_date] => 2016-08-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 28 [patent_figures_cnt] => 28 [patent_no_of_words] => 16599 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15248779 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11395179 [patent_doc_number] => 20170015713 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-01-19 [patent_title] => 'Fusion Protein Comprising Diphtheria Toxin Non-Toxic Mutant CRM197 or Fragment Thereof' [patent_app_type] => utility [patent_app_number] => 15/248850 [patent_app_country] => US [patent_app_date] => 2016-08-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 28 [patent_figures_cnt] => 28 [patent_no_of_words] => 16592 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15248850 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11443481 [patent_doc_number] => 20170044503 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-02-16 [patent_title] => 'ADAPTED RHINOVIRUS C' [patent_app_type] => utility [patent_app_number] => 15/232913 [patent_app_country] => US [patent_app_date] => 2016-08-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 12 [patent_figures_cnt] => 12 [patent_no_of_words] => 8157 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15232913 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11469675 [patent_doc_number] => 20170056458 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-03-02 [patent_title] => 'ONCOLYTIC ADENOVIRUS ENCODING A B7 PROTEIN OR ACTIVE FRAGMENT' [patent_app_type] => utility [patent_app_number] => 15/231422 [patent_app_country] => US [patent_app_date] => 2016-08-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 70 [patent_figures_cnt] => 70 [patent_no_of_words] => 33991 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15231422 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12193883 [patent_doc_number] => 09897606 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-02-20 [patent_title] => 'Reagents and methods for detecting influenza' [patent_app_type] => utility [patent_app_number] => 15/219976 [patent_app_country] => US [patent_app_date] => 2016-07-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 7 [patent_no_of_words] => 6906 [patent_no_of_claims] => 7 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 56 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15219976 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11120677 [patent_doc_number] => 20160317652 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-11-03 [patent_title] => 'Nucleic Acid Molecule Encoding Hepatitis B Virus Core Protein And Vaccine Comprising The Same' [patent_app_type] => utility [patent_app_number] => 15/213747 [patent_app_country] => US [patent_app_date] => 2016-07-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 25 [patent_figures_cnt] => 25 [patent_no_of_words] => 14437 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15213747 [rel_patent_id] =>[rel_patent_doc_number] =>)